SPEAKERS

SPEAKERS

Paul Richardson, MD

Director of Clinical Research, Jerome Lipper Multiple Myeloma Center
Clinical Program Leader, Dana Farber Cancer Institute
RJ Corman Professor of Medicine, Harvard Medical School
Boston, MA

After completing certifications in Internal Medicine, Hematology, and Medical Oncology, Dr. Paul Richardson joined the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute in 1999 and became Clinical Director in 2001, where he has played a pivotal role in advancing multiple myeloma treatment. He helped develop several landmark therapies, including bortezomib, lenalidomide, pomalidomide, panobinostat, ixazomib, and breakthrough immunotherapies such as elotuzumab, daratumumab, and isatuximab, while also contributing to the development of belantamab mafodotin, melflufen, selinexor, and novel CELMoDs for relapsed and refractory myeloma. Over the past decade, he has led the development and global adoption of the lenalidomide, bortezomib, and dexamethasone (RVD) regimen, including its integration into the influential IFM/DFCI clinical trials for newly diagnosed patients, with findings published in the New England Journal of Medicine and presented at ASCO. Dr. Richardson has authored more than 800 publications, held numerous leadership roles in organizations such as the Multiple Myeloma Research Consortium, ASCO, and the Alliance Myeloma Committee, and has received multiple prestigious awards recognizing his contributions to clinical research and patient care, including the Warren Alpert Foundation Prize, the ASH Ernest Beutler Prize, the IMF Robert A. Kyle Lifetime Achievement Award, and the Giants of Cancer Care Award.

Sonali Smith, MD

Elwood V. Jensen Professor of Medicine
Section Chief, Hematology/Oncology
University of Chicago
Chicago, IL

Dr. Sonali M. Smith is the Elwood V. Jensen Professor of Medicine, Section Chief of Hematology/Oncology and Co-Leader of the Cancer Service Line at the University of Chicago in the Department of Medicine. She is a clinical investigator in lymphoma and a clinical expert in Hodgkin and non-Hodgkin lymphomas. As faculty member at the University of Chicago since 2001, she has over 200 publications in peer-reviewed journals and has written over 25 review articles on lymphoid malignancies. She is particularly interested in targeted agents and pathway inhibitors, and has first and senior author publications through cooperative group trials and investigator-initiated trials. She has leadership roles including Chair of the SWOG Lymphoma Committee, past-Chair of the Lymphoma Research Foundation Scientific Advisory Board, past-chair of the ASCO Communications Committee, past-Chair of the ASCO Annual Meeting Scientific Committee (2022), co-chair of the 2022 AACR Advances in Malignant Lymphoma, and co-chair of the ASH Meeting on Hematologic Malignancies. In 2025, she was elected to the American Society of Clinical Oncology Board of Directors. She is one of the founding members and Steering Committee members of the international Women in Lymphoma (WiL) group. She has won numerous teaching awards and considers mentorship a key aspect of her career.

ALLIED HEALTH PROFESSIONALS PROGRAM SPEAKERS